Prestige Consumer Healthcare Inc.
$49.63+$0.03 (+0.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.2B
- P/E
- 11.3x
- EV / EBITDA
- 9.5x
- Revenue
- $1.1B
- Net margin
- 17.5%
- ROCE
- 9.2%
Price chart
Technical chartScreen technicals →-16.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +0.5%
- 3M
- -1.8%
- 6M
- +5.2%
- 1Y
- -16.1%
- 5Y
- -14.8%
52-week range
Day change +$0.03 (+0.1%) from $50 to $50 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PBH, bought on each weekday since 2021.
News & filings
What Prestige Consumer Healthcare filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating margin of 28.4% against a peer median of 8.9%.
Concerns (1)
- The P/E of 11.3 is 110% above the peer median of 5.4.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2026
Rule-based from financial data. Not advice.
About the company
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Read moreShow less
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
- Sector
- Healthcare
- Shares outstanding
- 48.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.2B
- P/E
- 11.3x
- P/B
- 1.1x
- EV / EBITDA
- 9.5x
- EV / Sales
- 2.9x
- P/S
- 2.0x
- 52-week high
- $70.21
- 52-week low
- $42.98
Profitability
- Operating margin
- 28.4%
- Net margin
- 17.5%
- EBITDA margin
- 30.4%
- ROE
- 10.1%
- ROCE
- 9.2%
- ROA
- 5.4%
- Asset turnover
- 0.31
Growth
- RevenueFY2026, the latest fiscal year in the company's growth history.
- $1.1B
- Revenue growth, 1YFY2026, the latest fiscal year in the company's growth history.
- -4.3%
- Revenue CAGR, 3YFY2026, the latest fiscal year in the company's growth history.
- -1.2%
- Net profit growth, 1YFY2026, the latest fiscal year in the company's growth history.
- -11.3%
- Free cash flowFY2026, the latest fiscal year in the company's growth history.
- $246.4M
Solvency
- Current ratio
- 3.57
- Debt / Equity
- 0.55
- Debt / Assets
- 0.30
- CFO / Net profit
- 1.35
- Cash / Market cap
- 3.0%
Where the revenue went
Of every $100 of FY2026 revenue, $17 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $493.1M |
| Revenue | Gross profit | $595.6M |
| Gross profit | Selling, general and administrative | $265.2M |
| Gross profit | Other operating expenses | $20.9M |
| Gross profit | Operating income | $309.4M |
| Operating income | Pretax income | $257.5M |
| Operating income | Interest and other expense | $51.9M |
| Pretax income | Tax and other | $67.2M |
| Pretax income | Net income | $190.3M |
Revenue and net profit
Revenue fell 4.3% in FY2026; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2023 | $1.1B | -$82.3M |
| FY2024 | $1.1B | $209.3M |
| FY2025 | $1.1B | $214.6M |
| FY2026 | $1.1B | $190.3M |
Cash flows
FY2026: $257.6M from operations, $246.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2023 | $229.7M | $221.9M |
| FY2024 | $248.9M | $239.4M |
| FY2025 | $251.5M | $243.3M |
| FY2026 | $257.6M | $246.4M |
Growth
Latest fiscal year 2026: each figure with its change over the year before.
- Revenue
- $1.1B-4.3%1Y
- EBITDA
- $331.1M-8.5%1Y
- Net profit
- $190.3M-11.3%1Y
- Cash from operations
- $257.6M+2.4%1Y
- Free cash flow
- $246.4M+1.3%1Y
- Revenue CAGR, 3Y
- -1.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2026 | $1.1B | $331.1M | $190.3M | $246.4M | 10.1% | -4.3% | -11.3% |
Monthly returns
Month-by-month returns of PBH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2026.
| Line | FY2026 |
|---|---|
| Assets | $3.5B |
| Current assets | $431.5M |
| Non-current assets | $3.1B |
| Liabilities | $1.6B |
| Current liabilities | $120.9M |
| Non-current liabilities | $1.5B |
| Equity | $1.9B |
| Paid-in capital | $608.5M |
| Retained earnings | $1.7B |
| Treasury stock | $439.3M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PBH highlighted.
P/E against peers
PBH trades at 11.3x earnings against a peer median of 5.4x (a 110% premium).
Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Prestige Consumer Healthcare Inc.PBHthis companyP/E ↑ premium | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| Supernus Pharmaceuticals, Inc.SUPN | $2.6B | -67.3x | 2.4x | -3.6% | 58.9x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| LeMaitre Vascular, Inc.LMAT | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Select Medical Holdings CorporationSEM | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Neogen CorporationNEOG | $2.0B | -1.8x | 1.0x | -52.7% | -2.9x |
| ADMA Biologics, Inc.ADMA | $1.8B | 12.6x | 3.9x | 30.8% | 9.3x |
| Sarepta Therapeutics, Inc.SRPT | $1.8B | -2.5x | 1.5x | -62.5% | -3.2x |
| Peer median | — | 5.4x | 2.0x | 2.5% | 9.3x |
Year-to-date ROI
PBH since 1 January, against earlier years.
Historical volatility
PBH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2023 | 30.8% |
| FY2024 | 30.4% |
| FY2025 | 30.7% |
| FY2026 | 28.4% |
| Line | FY2026 |
|---|---|
| RevenueTotal Revenue | $1.1B |
| Cost of revenueCost Of Revenue | $493.1M |
| Gross profitGross Profit | $595.6M |
| Operating expensesOperating Expense | $286.2M |
| Selling, general and administrativeSelling General And Administration | $265.2M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $20.9M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $20.9M |
| Total expensesTotal Expenses | $779.3M |
| Operating incomeOperating Income | $309.4M |
| Interest and other | |
| Pretax incomePretax Income | $257.5M |
| TaxTax Provision | $67.2M |
| Net incomeNet Income | $190.3M |
| Per share | |
| Supplementary |
| Line | FY2026 |
|---|---|
| AssetsTotal Assets | $3.5B |
| Current assetsCurrent Assets | $431.5M |
| Non-current assetsTotal Non Current Assets | $3.1B |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.6B |
| Current liabilitiesCurrent Liabilities | $120.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.5B |
| EquityTotal Equity Gross Minority Interest | $1.9B |
| Supplementary |
| Line | FY2026 |
|---|---|
| Operating cash flowOperating Cash Flow | $257.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $257.6M |
| Net income, continuing operationsNet Income From Continuing Operations | $190.3M |
| Depreciation and amortisationDepreciation And Amortization | $31.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $31.3M |
| Stock-based compensationStock Based Compensation | $10.8M |
| Deferred taxDeferred Tax | $22.7M |
| Deferred income taxDeferred Income Tax | $22.7M |
| Operating gains and lossesOperating Gains Losses | $160.0k |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $160.0k |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Change in working capitalChange In Working Capital | -$17.6M |
| Other non-cash itemsOther Non Cash Items | $20.0M |
| Investing cash flowInvesting Cash Flow | -$136.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$136.8M |
| Capital expenditureCapital Expenditure | -$11.2M |
| Purchase of PP&EPurchase Of PPE | -$11.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$11.2M |
| AcquisitionsPurchase Of Business | -$123.7M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$123.7M |
| Other investing changesNet Other Investing Changes | -$1.9M |
| Financing cash flowFinancing Cash Flow | -$156.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$156.1M |
| Debt issuedIssuance Of Debt | $43.0M |
| Debt repaidRepayment Of Debt | -$42.5M |
| Net debt issuedNet Issuance Payments Of Debt | $500.0k |
| Short-term debt issuedShort Term Debt Issuance | $43.0M |
| Short-term debt repaidShort Term Debt Payments | -$40.0M |
| Net short-term debt issuedNet Short Term Debt Issuance | $3.0M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$2.5M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$2.5M |
| Net common stock issuedNet Common Stock Issuance | -$156.3M |
| Common stock repurchasedCommon Stock Payments | -$156.3M |
| Share buybacksRepurchase Of Capital Stock | -$156.3M |
| Stock options exercisedProceeds From Stock Option Exercised | $4.3M |
| Other financing chargesNet Other Financing Charges | -$4.6M |
| Change in cashChanges In Cash | -$35.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 126.0% |
| Cash at the start of the yearBeginning Cash Position | $97.9M |
| Cash at the end of the yearEnd Cash Position | $63.9M |
| Free cash flowFree Cash Flow | $246.4M |
| Supplemental |
Learn while you research
Academy chapters picked for Prestige Consumer Healthcare Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 11.3 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read